• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169607 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page    p4 N" @0 I! i/ g

1 y! I0 x' @) w+ \  S5 v* m2 f& }, w& ]3 y3 d
Sub-category:) ?  l' G% U# C9 B0 Q3 B
Molecular Targets # ^! H) h1 D6 R# G
6 w- w. H: c1 y; q

* }8 a3 {5 W- l  b/ V; i0 gCategory:# t/ W$ V+ F( V( L9 p, Q7 h- ~
Tumor Biology - c& ]" o+ }, u0 \: h+ ?
8 b) F* H0 I8 x; B. }2 L
- D8 \9 k6 l& S' m6 c- Y- b; U
Meeting:, m5 L8 f! W8 }: H& A- d' h
2011 ASCO Annual Meeting
6 w3 b# ^9 [" _; M2 u# s, `* X5 X% }: A& S

3 s7 q5 V! S& ?6 x8 HSession Type and Session Title:% A+ O: ^/ t$ m8 C
Poster Discussion Session, Tumor Biology 2 F) i2 R9 `, C0 x

& F' ~  ]- Y8 t! W4 A1 a
* T& C, f" b9 ZAbstract No:
' O+ i& ?; T) F  |2 w10517 . A7 E$ _, R3 u) d

' J, W5 |( p5 S  S3 K3 Q8 }" N7 b1 |# b* L
Citation:
9 t0 g  g) ?% {% D0 VJ Clin Oncol 29: 2011 (suppl; abstr 10517) . Y+ f6 {8 [3 X" O- V, _3 F  D
6 q( [4 x; q; A3 Y8 h3 q. d3 o% z
6 I1 F& r8 {. A9 {7 L' _7 L- M
Author(s):3 q3 c) R; T/ k  V6 }* E" X( W
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ! f, U. `! k( L+ s1 D1 [

' _. Z% v( N- H' y7 v' ~; K# b
$ i% K7 @. C  u/ L
# ^0 O1 Q8 L) `) CAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! t/ {- \0 B4 O% Q0 J

' {8 H; o. P1 z, A7 k) g9 IAbstract Disclosures
) C# m! p# J1 r; m0 e8 h
. \0 i$ V2 ?2 b8 s, YAbstract:& Q5 h8 z1 l0 c# x7 Z7 \" f( L
) ]- @: J; K: G" q# z+ S
4 S' j% g, a2 J8 e6 U" R
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# O- ~' ?- D9 @8 `3 D

8 P  M0 X7 f) A# z1 @
& V1 p8 \6 p- r, L; J! K! A& S; I' z
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 * G. s+ g. |! ^1 F# g8 A. g( z
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
  J* ~) _) Q: C
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 3 F- X- d1 k* y/ d7 c* D
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。  ]/ z' v, p' `, t. T( Q6 u( R9 D
ALK一个指标医院要900多 ...
, ~& S( V$ x6 g2 b& g
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
/ c: P# P" _- ^2 v4 |3 w: x" w8 B# ^
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表